ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0682

Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up

Gustavo Balbi1, Guilherme de Jesús2 and Flavio Victor Signorelli2, 1Universidade de São Paulo, São Paulo, Brazil, 2Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil

Meeting: ACR Convergence 2022

Keywords: antiphospholipid syndrome, Cardiovascular, prognostic factors, risk factors

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: To estimate the incidence rate of new thrombotic events in a large single-center prospective cohort of primary antiphospholipid syndrome (PAPS) patients after approximately 5.5 years of its creation, and to understand risk factors associated with the occurrence of a first incident thrombotic event.

Methods: All patients fulfilled the updated criteria for thrombotic PAPS. For the calculation of the incident thrombosis rate, patients could contribute with more than one event since all of them were continuously at risk of thrombotic events. For the analysis of risk factors associated with the occurrence of a first incident thrombotic event, patients were followed until the occurrence of a first thrombotic event (incident cases) or until their last outpatient visit (non-incident cases). For statistical analysis, we used Kaplan-Meier curves, log-rank test, and Cox proportional hazards (including variables with p< 0.10 in the univariate analysis), as appropriate.

Results: We included 135 PAPS patients. Most of them were females (85.2%) and the mean age at baseline was 43.2±12.6. Arterial hypertension and diabetes were present in 40.0% and 10.4%, respectively (Table 1). Total follow-up was 601.8 patients-year. During our study, 23 thrombotic events (10 ischemic strokes, 12 venous thromboses, and 1 thrombotic microangiopathy) were diagnosed in 20 patients, which led to an incidence rate of 3.82 cases per 100 patients-year. INR values at the time of thrombosis were known in 19 events; in 12 of them (63.2%), INR was within the proposed target. When we analyzed the occurrence of a first thrombotic event, the cumulative incidence was 14.8% at the end of 66 months. The mean time for the occurrence of a first thrombotic event was 33±19.4 months. In the multivariate analysis, diabetes independently correlated with the occurrence of a first thrombotic event (HR 3.3, CI95% 1.1-5.6, p=0.021) (Table 2 / Figure 1).

Conclusion: Incident thrombotic events were common in our cohort, most of them with INR within target. Diabetes was associated with a 3-fold risk of a new first thrombotic event in primary APS patients.

Supporting image 1

Table 1. Characteristics of patients with Primary Antiphospholipid Syndrome from APS-Rio cohort

Supporting image 2

Table 2. Univariate and multivariate analyses of potential risk factors associated with incident thrombosis in PAPS patients.

Supporting image 3

Figure 1. Survival analysis of first new thrombotic event, comparing PAPS patients with and without diabetes.


Disclosures: G. Balbi, None; G. de Jesús, None; F. Signorelli, None.

To cite this abstract in AMA style:

Balbi G, de Jesús G, Signorelli F. Analysis of Recurrent Thrombotic Events in a Large Single-center Primary Antiphospholipid Syndrome Cohort: Results from APS-Rio Cohort After over Than 600 Patients-year of Follow-up [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/analysis-of-recurrent-thrombotic-events-in-a-large-single-center-primary-antiphospholipid-syndrome-cohort-results-from-aps-rio-cohort-after-over-than-600-patients-year-of-follow-up/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-recurrent-thrombotic-events-in-a-large-single-center-primary-antiphospholipid-syndrome-cohort-results-from-aps-rio-cohort-after-over-than-600-patients-year-of-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology